But that bargain broke down with biologic drugs, medicines made from living cells. When Congress wrote the Biologics Price Competition and Innovation act, the pharmaceutical industry rigged the rules. Between 2007 and 2009, Big Pharma spent hundreds of millions of dollars lobbying to make biosimilar approval far more difficult and expensive. They claimed that biologics were too delicate, they were too mystical to allow true generics. They compared them during these lobbying sessions to fine wines. (01:38–01:50)
CLAIM
Asserts that pharmaceutical companies spent heavily on lobbying to complicate biosimilar approval.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.
